Romiplostim

Nature Reviews Drug Discovery

Volumn 7, Issue 11, 2008, Pages 887-888

  Cines, Douglas B ^a   Yasothan, Uma ^b   Kirkpatrick, Peter ^c  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b IQVIA   (United States)

^c Nature Reviews Drug Discovery ^*

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; DEXAMETHASONE; ELTROMBOPAG; HORMONE RECEPTOR STIMULATING AGENT; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; NPLATE; PLACEBO; REMIPLISTIM; RITUXIMAB; THROMBOPOIETIN RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL TRIAL; DRUG APPROVAL; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; FOOD AND DRUG ADMINISTRATION; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; PRIORITY JOURNAL; SPLENECTOMY; THROMBOCYTOPENIA; UNITED STATES;

CARRIER PROTEINS; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; HUMANS; RECEPTORS, FC; RECEPTORS, THROMBOPOIETIN; SPLENECTOMY; THROMBOCYTOPENIA; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 55349124018     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2741     Document Type: Article

References (18)

1. Cines, D. B. & Blanchette, V. S. Immune thrombocytopenic purpura. N. Engl. J. Med. 346, 995-1008 (2002).
2. Ballem, P. J. et al. Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura. Evidence of both impaired platelet production and increased platelet clearance. J. Clin. Invest. 80, 33-40 (1987).
3. Kaushansky, K. Historical review: Megakaryopoiesis and thrombopoiesis. Blood 111, 981-986 (2008).
4. Nomura, S. et al. Effects of pegylated recombinant human megakaryocyte growth and development factor in patients with idiopathic thrombocytopenic purpura. Blood 100, 728-730 (2002).
5. Li, J. et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 98, 3241-3248 (2001).
6. Broudy, V. C. & Lin, N. L. AMG531 stimulates megakaryopoiesis in vitro by binding to Mpl. Cytokine 25, 52-60 (2004).
7. Food and Drug Administration. FDA labelling information. FDA web site [online], (2008).
8. Wang, B. et al. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin. Pharmacol. Ther. 76, 628-638 (2004).
9. Bussel, J. B. et al. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N. Engl. J. Med. 355, 1672-1681 (2006).
10. Kuter, D. J. et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: A double-blind randomised controlled trial. Lancet 371, 395-403 (2008).
11. Cooper N. et al. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br. J. Haematol. 125, 232-239 (2004).
12. Godeau, B. et al. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study. Blood 112 999-1004 (2008).
13. Cohen, Y. C. et al. The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Arch. Int. Med. 160, 1630-1638 (2000).
14. Bussel, J. B. et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N. Engl. J. Med. 357, 2237-2247 (2007).
15. McHutchison, J. G. et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N. Engl. J. Med. 357, 2227-2236 (2007).
16. Holley, B. et al. Oppenheimer Equity Research Report (Oppenheimer, 25 Aug 2008).
17. IMS MIDAS (2007).
18. To, A. Amgen (Natixis Bleichroeder, 06 March 2008).